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Abstract
Background: The aim of this treatment planning study was to investigate the potential advantages
of intensity-modulated (IM) proton therapy (IMPT) compared with IM photon therapy (IMRT) in
nasopharyngeal carcinoma (NPC).
Methods: Eight NPC patients were chosen. The dose prescriptions in cobalt Gray equivalent (GyE)
for gross tumor volumes of the primary tumor (GTV-T), planning target volumes of GTV-T and
metastatic (PTV-TN) and elective (PTV-N) lymph node stations were 72.6 GyE, 66 GyE, and 52.8
GyE, respectively. For each patient, nine coplanar fields IMRT with step-and-shoot technique and
3D spot-scanned three coplanar fields IMPT plans were prepared. Both modalities were planned in
33 fractions to be delivered with a simultaneous integrated boost technique. All plans were
prepared and optimized by using the research version of the inverse treatment planning system
KonRad (DKFZ, Heidelberg).
Results: Both treatment techniques were equal in terms of averaged mean dose to target volumes.
IMPT plans significantly improved the tumor coverage and conformation (P < 0.05) and they
reduced the averaged mean dose to several organs at risk (OARs) by a factor of 2–3. The low-to-
medium dose volumes (0.33–13.2 GyE) were more than doubled by IMRT plans.
Conclusion: In radiotherapy of NPC patients, three-field IMPT has greater potential than nine-
field IMRT with respect to tumor coverage and reduction of the integral dose to OARs and non-
specific normal tissues. The practicality of IMPT in NPC deserves further exploration when this
technique becomes available on wider clinical scale.
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Background
Radiotherapy (RT) of nasopharyngeal carcinoma (NPC) is
a challenging task. While distant dissemination is the
most common site of failure, local recurrence occurs still
in more than one-third of patients with locally advanced
disease (T3–T4) treated with two-dimensional RT (2D-
RT) only [1]. Furthermore, the nasopharyngeal cavity is
surrounded by critical neural tissues and sensitive struc-
tures such as auditory apparatus, temporomandibular
(TM) joints, and parotid glands whose normal function-
ing is essential for maintenance of the patients' overall
well-being. A quality of life (QoL) study of patients with
head and neck cancer by Huguenin et al. [2] revealed that
NPC patients had the highest morbidity probably as the
result of using large RT fields which included the salivary
glands and TM joints. In another QoL survey of disease-
free NPC patients, xerostomia, hearing impairment, dys-
phagia and trismus were reported as the most frequent
side effects when RT was delivered by conventional tech-
niques [3,4]. Since implementation of three-dimensional
conformal RT (3D-CRT), clear definition of target vol-
umes and organs at risk (OARs) and accurate estimation
of tissue heterogeneities have become available which
may account for the 3-year local control rate above 80%
for T3–T4 tumors reported in some studies [5]. Neverthe-
less, simultaneous protection of several OARs and optimi-
zation of dose homogeneity and conformity to the
concave and often irregularly-shaped target volumes in
NPC have been beyond the operational scope of 3D-CRT.
In recent years, intensity-modulated RT using photons
(IMRT) have been applied clinically for NPC patients for
whom the dosimetric advantges of this technique have
contributed to improving tumor-free survival rates and
reducing RT-related side effects such as xerostomia [6,7].
However, for T3–T4 tumors, a 3-year local failure rate of
17% is reported despite using whole course IMRT [7].
Interestingly, while evaluation of QoL scores (EORTC
QLQ-C30 and EORTC QLQ-HN35) in NPC patients has
revealed the superiority of 3D-CRT or IMRT over 2D-RT +/
- 3D-CRT techniques, it could not show any significant
difference between 3D-CRT and IMRT [8].
Recently, much interest is devoted to application of pro-
tons in the treatment of head and neck cancers [9-11]. The
dosimetric characteristics of protons, with sharp distal
fall-off of the dose in combination with technical
improvements in treatment planning and dose delivery
using intensity modulation (IMPT) and 3D spot-scanning
[12-14] can lead to more conformal dose distributions of
protons in vivo. The advantages of IMPT over state-of-the-
art IMRT in the head and neck region have been demon-
strated by comparative planning studies [15,16] revealing
dosimetric benefits, essentially by lowering the integral
dose in OARs and non-critical normal tissues.
In this paper, we present a simulation study which inves-
tigates the potential benefits of IMPT over IMRT in the
treatment of NPC patients with regard to target volumes,
OARs and non-specific normal tissues. Since this project is
a simulation work, the predictive effects of tumour histol-
ogy or chemotherapy were not taken into consideration.
Methods
Patient selection and target/OAR definition
Eight patients including two pediatric cases, with a histo-
logically proven diagnosis of NPC were selected. These
patients were being treated at the Department of Radio-
therapy, Sahlgrenska University Hospital, Göteborg, Swe-
den. Their TNM stages according to the 1997 American
Joint Committee on Cancer staging system were: T1N0M0;
T1N1M0; T2aN3aM0; T2bN3bM0; T3N2M0; T3N3bM0; T4N1M0;
T4N2M0. The original CT data sets with a slice thickness of
5–7 mm and no interslice gap were acquired and trans-
ferred to the treatment planning system, VIRTUOS, avail-
able at the German Cancer Research Center (DKFZ),
Heidelberg, Germany for target definition. Based on the
clinical data and pre-therapy diagnostic CT/MR images,
the gross tumor volume of the primary tumor (GTV-T)
and of the nodal metastases (GTV-N) were re-delineated
on each CT slice. Two sets of clinical target volumes (CTV)
were defined for each patient. CTV-TN was defined as the
volume encompassing GTV-T and GTV-N, when present,
with a 10 mm margin in all directions. The whole of the
nasopharyneal cavity was also included in this volume.
CTV-N consisted of the volume of the bilateral cervical
lymph node stations in levels Ib to V, medial supraclavic-
ular fossae, retro/parapharyngeal spaces, the posterior
nasal cavity and maxillary sinuses, inferior sphenoidal
body, clivus, and pterygoid fossae. To account for set-up
errors and patient movements, two sets of planning target
volumes (PTV-TN, and PTV-N) were also defined by add-
ing a 5 mm margin to each corresponding CTV. All PTVs
and CTVs were modified wherever they encountered neu-
ral tissues or bony structures without evidence of tumor
infiltration. For example, for cases with T1–T2 disease or
when delineating the cervical lymph node stations, only
surface of the clivus and cervical vertebrae were included
in PTV-TN and PTV-N, respectively. Likewise for T3–T4
tumors, in the regions where GTV-T was in close vicinity
of the brainstem or optic nerves, there was no margin
between GTV-T and PTV-TN meaning that the outer
bounderies of both target volumes were the same in these
particular regions. Since there was no clinical evidence of
skin infiltration by GTV-T or GTV-N in any of the patients,
PTV-TNs and PTV-Ns were always modified so that they
did not extend into or out of the skin.
The mean volumes for GTV-T, PTV-TN, and PTV-N were
24.4 cc (4.3–56.1), 287.8 cc (100.9–428.7) and 450.3 cc
(157.4–993.6), respectively. Besides the standard OARsRadiation Oncology 2008, 3:4 http://www.ro-journal.com/content/3/1/4
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(spinal cord, brainstem, temporal lobes, the optic appara-
tus and parotid glands), the inner and middle/external
ears, cerebellum and posterior brain tissue up to the levels
of the clinoids, skin, TM joints, pituitary and thyroid
glands, larynx/esophagus, and the oral cavity were also
delineated. All target volumes and OARs were delineated
by the same radiation oncologist. The use of same treat-
ment planning system to prepare both the IMRT and
IMPT plans eliminated the risk of discrepancies for any
calculated volume.
Dose prescription and treatment planning
Dose prescriptions in cobalt Gray equivalent (GyE) to
GTV-T, PTV-TN and PTV-N were 72.6 GyE, 66 GyE, and
52.8 GyE, respectively. In dose prescriptions to the target
volumes and OARs, a relative biological effectiveness
(RBE) of 1.1 to Co60 was assumed for the protons. The pre-
scribed doses were normalized to the median dose of the
target volumes. Both IMRT and IMPT plans were prepared
for each patient to be delivered in 33 fractions with the
simultaneous integrated boost technique.
For prepration of IMRT and IMPT plans, the research ver-
sion of the inverse treatment planning system KonRad
(DKFZ, Heidelberg) integrated into the VIRTUOS plan-
ning system was used. In IMRT plannings, nine coplanar,
equally spaced, 6 MV photon beams were used. For defi-
nition of the fluence map, five non-zero intensity levels
were chosen. The optimized intensity profile for each
beam was then translated into a set of leaf positions for a
multileaf collimator, with a resolution of 10 mm at iso-
center, simulating a step-and-shoot delivery technique.
On average, 132 segments were used for each IMRT plan.
In IMPT plans, three coplanar fields (0°, 45°, 315° or 0°,
60°, 300°) were applied. In proton therapy, when target
volumes are located in front of critical neural structures
such as the spinal cord, an anterior field is usually avoided
in order to prevent the distal edge of highly weighted
Bragg peaks with uncertain RBEs abutting against the
organ. However, for our NPC patients an anterior field
was chosen instead of a posterior field to avoid unneces-
sary exposure of the neural tissues (Cerebellum) behind
the nasopharyngeal cavity. For IMPT plannings, we used
the 3D spot-scanning technique in which the target vol-
umes were divided into a set of layers with equal radiolog-
ical depth. For each layer, the treatment planning system
generated a discrete beam weight map for regularly spaced
pencil beam spots (Bragg peaks) of protons with lateral
separation of 5 mm and depth modulation of 3 mm. The
initial Full Width at Half Maximum of the proton pencil
beams at the patient surface was set to 6 mm. The exact
number of the pencil beams were determined by the
geometry of the target volumes and the lateral separation
of the beam spots. On average, 24,734 spots (range;
15,812 – 39,156) were used for each beam. A simultane-
ous optimization of the relative weights of the individual
proton pencil beams for all three fields was performed by
using various pencil beam energies of 160–200 MeV to
create the desired dose distributions in the target volumes
and OARs.
The inverse optimization process of the plans for both
techniques was based on the user-defined dose/dose-vol-
ume constraints (Table 1) and relative penalty factors for
the target volumes and OARs. For both techniques, all
applied dose/dose-volume constraints were soft con-
straints and they were the same in terms of GyE.
In KonRad, each structure classified as target could have a
minimum dose, a maximum dose, and an associated pen-
alty factor. Structures classified as OARs could only have
maximum doses and associated penalty factors. Option-
ally, user-defined dose-volume histograms (DVH) could
be set for OARs in the program. Furthermore, for overlap-
ping structures (such as GTV-T and temporal lobes in a T4
tumor), the system had to be told which of the structures
Table 1: Dose/volume constraints for OARs in IMRT and IMPT plans
Volume Dose (GyE)
Spinal cord Dmax ≤ 50 GyE
Brainstem Dmax ≤ 60 GyE
Temporal lobes Dmax ≤ 65 GyE
TM joints Dmax ≤ 60 GyE
Optic chiasm & nerve Dmax ≤ 54 GyE
Eyes Dmax ≤ 25 GyE
Inner ears Dmean < 45 GyE
Mid-external ears Dmean < 40 GyE
Larynx-esophagus Dmean < 30 GyE
Thyroid gland Dmean < 30 GyE
Parotid glands (single gland) Dmean < 26 GyE
Pituitary gland as low as possible
Oral cavity as low as possible
GyE = cobalt Gray equivalent, TM = temporomandibular. Dmax is the absolute maximal dose in a single voxel.Radiation Oncology 2008, 3:4 http://www.ro-journal.com/content/3/1/4
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owned the voxels in the overlap region by assigning the
structures priority numbers. Based on the input parame-
ters for target volumes and OARs, KonRad used a single
objective iterative optimization algorithm (gradient tech-
nique) in order to improve the 3D dose distributions and
minimizing the objective functions.
The treatment planning and optimization of IMRT and
IMPT was started with cases showing least complex geom-
etry of the target volumes (T1N0M0 and T1N1M0). For
target volumes, the minimum and maximum doses were
set to be equal to the prescribed dose in order to achieve a
maximally homogeneous dose distribution within the tar-
get. The critical neural tissues (brainstem, spinal cord,
optic apparatus, and temporal lobes) and target volumes
were given the highest penalty factors. The initial penalty
factors for other OARs were dependent on the importance
of their function and their distance from target volumes.
For example, the assigned penalty factors for inner ears
were higher compared with the middle/external ears. An
iterative optimization of the plans was performed by
manually adjusting the dose constraints for OARs or pen-
alty factors in a trial-and-error procedure until satisfactory
dose distributions in the target volumes and OARs were
achieved. No attempt was made to further reduce the dose
to OARs below the dose constraints presented in Table 1.
The dose homogeneity and conformity aimed for the tar-
get volumes were:
a. dose homogeneity of -5% to +7%.
b. At least 95% of the target volume should receive 95%
of the prescribed dose.
c. No more than 5% of the target volume should receive
doses above 105% of the prescribed dose.
The actual dose constraints and penalty factors in the final
accepted plans from the first two NPC cases were used as
starting input parameters for optimization of IMRT and
IMPT plans in the subsequent cases. These parameters had
to be modified again in a trial-and-error fashion in loco-
regionally advanced cases in order to comply with the
planning goals for the target volumes and/or the tolerance
threshold of the critical OARs. In these cases, "optimiza-
tion only" volumes were also added in order to achieve
sharp dose gradients at the edge of the target volumes or
to reduce the dose in critical neural tissues such as tempo-
ral lobes. In those cases where GTV-T or PTV-TN was
extended into a critical neural structure, the latter organ
was given a higher overlapping priority than the target.
With this approach insufficient dose to some parts of the
high dose target volumes (GTV-T and PTV-TN) had to be
accepted.
Plan comparison
The IMRT and IMPT plans were compared using a set of
parameters derived from DVHs and dose-volume statis-
tics. Besides Dmean, we used D1 and D99, which were
defined as the dose received by 1% and 99% of the target
volume, respectively. V95 and V105 denoted the volumes
of the target that were covered with ≥ 95% and ≥ 105% of
the prescribed dose, respectively. The conformity index (CI)
was defined as the ratio between the V95 of the body and
the V95 of the target. The inhomogeneity coefficient (IC)
was defined as (Dmax  - Dmin)/Dmin. For PTV-TN and
PTV-N, all parameters were calculated for inclusive vol-
umes of the targets due to the limitations of the VIRTUOS
planning system in calculating exclusive volumes. The
term "inclusive volume" means that the volumes of GTV-
T and PTV-TN were included in the PTV-TN and PTV-N,
respectively, when calculating and extracting the dose-vol-
ume data for the latter targets. Ideally, when a target
encloses another one, dose-volume data for the first target
should be presented by excluding the dose contributions
from the enclosed target when this receives a dose other
than the enclosing target.
For comparison of OARs, we used Dmax and Dmean for
organs with mainly parallel structures and Dmax for those
with mainly serial structures. Dmax for OARs was defined
as the absolute maximal dose in a single voxel.
Statistics
Statistical analysis was performed using Wilcoxon signed
ranks tests applying SPSS 12.0.1 software for windows. A
two-tailed p-value of < 0.05 was accepted as significant.
Results
Targets
Table 2. presents the averaged dosimetric parameters for
all three target volumes, comparing IMPT with IMRT
plans. There were no significant differences in Dmean or
D99 for any target volume, except for the averaged D99 of
PTV-TN, which was significantly (2.8 GyE) lower in IMPT
plans. The averaged Dmean for PTV-N (59 GyE) in both
techniques was higher than the prescribed dose (52.8
GyE), which partly was a result of dose calculation for the
inclusive volume (including PTV-TN and GTV-T) of this
target. For all target volumes, D1  was always lower in
IMPT plans by an average value of 1.3 GyE. Similarly,
mean V105 values were lower in IMPT than IMRT plans
for all target volumes, although the difference for GTV-T
was not statistically significant. The averaged and individ-
ual values for V95 were almost always better in IMPT than
in IMRT plans, reflecting better tumor coverage. This
resulted in an increase of the averaged V95 by 3.4% for
PTV-N, 5.6% for PTV-TN, and 4.6% for GTV-T in IMPT
plans. Figure 1. shows the mean DVHs for target volumesRadiation Oncology 2008, 3:4 http://www.ro-journal.com/content/3/1/4
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Mean DVH curves of 8 NPC patients for target volumes comparing IMPT with IMRT Figure 1
Mean DVH curves of 8 NPC patients for target volumes comparing IMPT with IMRT.
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obtained for all eight NPC patients comparing IMPT with
IMRT plans.
The individual and mean values for CI were always better
in the IMPT plans for all targets except in one case
(T3N2M0) for PTV-TN, where they were almost equal for
both plans (1.07). In both techniques, the best CI values
were obtained for PTV-TN volumes (average value,1.02 vs.
1.12). The corresponding values were much higher for
GTV-T (average value; 2.36 vs. 4.68) reflecting the diffi-
culty both treatment techniques had in avoiding small
islands of 95% isodose in the rest of the treatment/target
volumes. The evaluation of dose inhomogeneity meas-
ured by IC showed significant superiority of IMPT for
GTV-T (mean value: 0.11 vs. 0.17). There was no signifi-
cant difference between the two techniques for other tar-
get volumes. However, the latter result could be
misleading since inclusive volumes of PTV-TN and PTV-N
were used for DVH calculations. Figure 2 and 3. present
the dose distribution in different planes for two NPC
cases.
Organs at risk
Table 3. compares the averaged dose parameters for OARs
between the IMPT and IMRT plans. In brief, the averaged
Dmax/Dmean for most of OARs was significantly lower in
the IMPT plans. Exceptions were the values for Dmax of
the brainstem, TM joints, oral cavity, pituitary gland, and
the skin and for Dmean of the pituitary gland. For locally
advanced tumors, IMPT plans had as much difficulty as
IMRT plans in lowering the Dmax to OARs located in the
vicinity of the GTV-T covered by the high isodoses. In
some of these cases, individual Dmax values (measured in
single voxel volumes) for the inner and middle/external
ears and TM joints were in fact somewhat higher in IMPT
plans. The dosimetric superiority of the IMPT plans was
reflected in the Dmean of OARs such as the auditory appa-
ratus, temporal lobes, TM joints, larynx/esophagus, and
thyroid gland, where the averaged values were one-third
to one-half of the corresponding values in the IMRT plans.
For the spinal cord, the averaged Dmax was halved by
IMPT plans. The averaged Dmax and Dmean for cerebel-
lum and posterior brain tissue up to the level of clinoids
were also significantly lower in IMPT plans (35 GyE and
0.5 GyE) compared to IMRT plans (57.2 GyE and 18.8 GyE)
even though these structures were not considered initially
in the optimization process. The averaged Dmax for the
skin was almost equal for both modalities (65.7 GyE vs.
66.8 GyE) but the averaged Dmean was significantly lower
Table 2: Mean dose-volume data and standard deviations for 8 NPC patients comparing IMPT with IMRT
Target Parameter IMPT IMRT P value
Mean +/- 1SD Mean +/- 1SD
GTV-T D99 66.6 6.1 64.9 4.2 0.195
D1 74.8 1.1 76.1 0.8 0.008
D. mean 72.4 0.4 72.2 0.4 0.148
SD 1.4 1.07 2.2 0.9 0.008
V95 97.6% 3% 93% 6% 0.016
V105 0.5% 0.9% 1.6% 2% 0.063
CI 2.36 1.07 4.69 3.59 0.008
IC 0.11 0.1 0.17 0.09 0.016
PTV-TN D99 52.5 4.2 55.3 2.2 0.039
D1 73.4 0.6 74.7 0.7 0.008
D. mean 66.5 0.4 66.5 0.2 0.844
SD 3.4 0.7 3.8 0.54 0.188
V95 93.3% 2% 87.7% 3% 0.008
V105 12.2% 5% 19.7% 4% 0.008
CI 1.02 0.07 1.12 0.12 0.016
IC 0.32 0.07 0.32 0.05 0.844
PTV-N D99 45 2.3 44.7 0.9 0.945
D1 72.5 1.2 73.6 1.2 0.008
D. mean 59.3 2.7 59.5 2.3 0.742
SD 6.7 0.84 7 0.92 0.219
V95 95.4% 2% 92.0% 2% 0.016
V105 52.9% 17.9% 60.5% 13.8% 0.047
CI 1.11 0.06 1.32 0.12 0.016
IC 0.55 0.07 0.6 0.05 0.383
All parameters are shown for the inclusive volumes of PTV-TN and PTV-N. SD = standard deviation, CI = conformity index, IC = inhomogeneity 
coefficient. Values for D99, D1, D. mean and SD are in cobalt Gray equivalent (GyE).Radiation Oncology 2008, 3:4 http://www.ro-journal.com/content/3/1/4
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in IMPT plans (5.7 GyE vs. 9.6 GyE). Figure 4. shows mean
DVHs of some OARs for the two modalities.
Non-specific normal tissue
The dose to non-specific normal tissues was measured by
calculating V50, V30, V20, V10, V1, and V0.5 of the body,
corresponding to the volumes of the 33 GyE, 19.8 GyE,
13.2 GyE, 6.6 GyE, 0.66 GyE, and 0.33 GyE isodoses. The
obtained results for each technique and for all eight
patients are shown in Figure 5. On average, for each of the
above isodoses, IMRT plans resulted in increments that
Comparison of dose distributions between IMPT (right) and IMRT (left) plans in T4N1M0 NPC in axial (above) and sagittal  (below) views Figure 2
Comparison of dose distributions between IMPT (right) and IMRT (left) plans in T4N1M0 NPC in axial (above) and sagittal 
(below) views. Dotted lines denote 95% of the prescribed dose to GTV-T.Radiation Oncology 2008, 3:4 http://www.ro-journal.com/content/3/1/4
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were 1.78, 1.99, 2.06, 2.11, 2.57 and 2.66-fold greater
than the IMPT plans.
Discussion
In terms of RT treatment planning, NPC is one of the most
difficult diagnoses in the head and neck region due to the
complex geometry of the tumor and the several critical
and functional structures surrounding the target. The clin-
ical advantages of IMRT in NPC have been demonstrated
through non-randomized clinical studies [6,7,17], which
show improved 2–4 year local/locoregional control rates
of 88–98%, no grade III xerostomia, and a reduced rate of
grade III–IV hearing loss to 7–15%. However, one prob-
lem with the published clinical data on IMRT of NPC
patients is the small sample size and short follow-up
period in evaluation of patterns of tumor failure and late
normal tissue reactions, including the risk of RT-induced
second malignancies. Furthermore, the high rate of tumor
Comparison of dose distributions between IMPT (right) and IMRT (left) plans in T2N3M0 NPC in axial (above) and coronal  (below) views Figure 3
Comparison of dose distributions between IMPT (right) and IMRT (left) plans in T2N3M0 NPC in axial (above) and coronal 
(below) views. Dotted lines denote 95% of the prescribed dose to PTV-TN.Radiation Oncology 2008, 3:4 http://www.ro-journal.com/content/3/1/4
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control in such studies could be confounded by the effects
of accelerated RT or combined modality treatment using
chemotherapy [18].
Recently, much effort has been dedicated to evaluating
proton therapy, especially IMPT, for different tumor sites
including the head and neck region [19-24]. Most of the
published data from the comparative planning studies
suggest equivalent levels of target conformation with both
IMRT and IMPT techniques. The superiority of IMPT is
attributed mostly to lower integral doses in OARs and
non-target volumes and to the possibility of dose escala-
tion to the tumor [15,20,22,25]. These observations are
partially supported by the results of the current study. In
our IMPT plans, the averaged D99 and D. mean did not
differ significantly from those for IMRT plans, except for
the averaged D99 of PTV-TN, which was, interestingly, 2.8
GyE lower in IMPT plans probably as the result of the lim-
ited number of the fields (three) used in preparation of
IMPT plans. In the case of GTV-T, however, averaged val-
ues for D1, V95, CI and IC were all significantly improved
by IMPT, even though the magnitude of the absolute dif-
ferences was more appreciable for V95  (4.6%) and CI
(2.33). Technically, tumor coverage was more compro-
mised in IMRT plans when targets were closely sur-
rounded by several critical OARs with maximum dose-
constraints below the prescribed dose to the target. The
typical cases were intracranially extended T4 tumors sur-
rounded by temporal lobes at both sides, the optic appa-
ratus in front and brainstem at back. This problem was
less pronounced in IMPT plans in which 3D modulation
of the fluences of the fields gave more degree of freedom
in the treatment planning.
It is possible that we could have improved the conformity
of the IMRT plans further by using higher intensity levels
than five when preparing the plans. However, the
expected gain would be slight as it has been suggested by
Longobardi et al. [26]. In their planning study of seven
patients with head and neck cancer in which IMRT with
Table 3: Mean dose parameters in GyE for OARs in 8 NPC patients planned with IMPT and IMRT
Organ/ IMPT IMRT IMPT/IMRT P value
Parameter Mean (Range) Mean (Range) Mean dose ratio
Optic chiasm
D. max 16.1 (0.0 – 52.3) 23.8 (4.8 – 56.8) 0.67 0.008
Spinal cord
D. max 16.7 (10.1 – 28.7) 46.0 (44.0 – 50.0) 0.36 0.008
Brainstem
D. max 47.3 (14.6 – 60.5) 58.7 (53.6 – 64.2) 0.80 0.055
Temp. lobe
D. max 57.2 (33.0 – 67.8) 61.8 (53.5 – 67.7) 0.92 0.021
D. mean 5.4 (0.5 – 12.3) 13.4 (8.4 – 20.3) 0.40 < 0.0001
Inner ear
D. max 36.3 (8.0 – 76.1) 51.8 (32.8 – 73.0) 0.70 0.009
D. mean 13.1 (1.1 – 43.9) 36.4 (21.8 – 53.0) 0.36 < 0.0001
Mid/ext ear
D. max 37.4 (8.0 – 70.4) 49.2 (33.0 – 68.2) 0.76 0.039
D. mean 8.1 (0.3 – 13.5) 24.5 (19.4 – 32.8) 0.33 < 0.0001
TM joint
D. max 54.9 (37.0 – 73.0) 60.5 (45.9 – 71.4) 0.90 0.252
D. mean 17.4 (7.3 – 28.9) 38.8 (27.9 – 54.6) 0.44 < 0.0001
Larynx/esophgus
D. max 52.8 (46.6 – 64.4) 57.9 (52.3 – 64.1) 0.91 0.039
D. mean 14.3 (8.6 – 18.5) 30.6 (24.3 – 35.3) 0.46 0.008
Oral cavity
D. max 70.2 (68.6 – 73.9) 72.1 (70.4 – 74.4) 0.97 0.055
D. mean 38.1 (33.9 – 43.7) 44.0 (40.5 – 46.7) 0.86 0.016
Pituitary gl.
D. max 44.9 (3.2 – 73.0) 53.5 (20.6 – 73.8) 0.84 0.055
D. mean 34.8 (1.1 – 71.0) 42.2 (11.6 – 65.9) 0.82 0.148
Thyroid gl.
D. max 51.5 (42.4 – 64.2) 57.5 (52.9 – 64.9) 0.89 0.008
D. mean 19.8 (12.5 – 24.4) 38.2 (33.7 – 45.4) 0.52 0.008
Parotid gl.
D. mean 36.3 (23.6 – 44.3) 40.0 (26.0 – 49.0) 0.91 0.011
GyE = cobalt Gray equivalent, TM = temporomandibular, Mid/ext = middle/external. D. max is the absolute maximal dose in a single voxel.Radiation Oncology 2008, 3:4 http://www.ro-journal.com/content/3/1/4
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Mean DVHs for OARs comparing IMPT with IMRT Figure 4
Mean DVHs for OARs comparing IMPT with IMRT.
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step and shoot technique and various intensity levels of 5,
10, and 20 were included, doses of 54 Gy and 64.8–70.2
Gy were prescribed for PTV1 and PTV2 (boost volume),
respectively. The authors reported V95 values of 94%,
95.4%, and 95.9% for the three intensity levels for PTV1.
Corresponding values for PTV2 were 86.4%, 87.9%, and
87.9% respectively.
We must point out that the optimization of the beam
intensity profiles in our IMRT and IMPT plannings were
based on a single objective inverse treatment planning
algorithm. One of the inherent limitations of this
approach is the fact that choice of the input parameters
such as interstructural penalty factors in achieving an opti-
mal plan is a trial-and-error procedure and it is based on
the empirical knowledge of the planner. Besides being
time consuming depending on the number of optimiza-
tion cycles, single objective inverse treatment planning
does not explore the optimization search space to its full
extent and in the end, it is not certain whether an accepted
plan is the best clinically achievable solution. Recently,
multicriteria optimization systems for inverse treatment
planning in RT has been introduced [27]. With this
approach, a large collection of clinically relevant treat-
ment plans based on the pareto-optimal solution is
precomputed and as the result the trial-and-error
approach in the optimization step is avoided. Through
navigation in a multidimensional plan space, the user can
identify the advantageous trade-offs in competing plans
and select the plan that achieves the optimal clinical
Volumes of low-medium isodoses (0.5%–50%) in IMPT and IMRT for 8 NPC patients Figure 5
Volumes of low-medium isodoses (0.5%–50%) in IMPT and IMRT for 8 NPC patients.
0
2000
4000
6000
8000
10000
12000
14000
V50 V30 V20 V10 V1 V0.5
Dose/volume parameter (IMPT)
V
o
l
u
m
e
 
(
c
c
)
0
2000
4000
6000
8000
10000
12000
14000
V50 V30 V20 V10 V1 V0.5
Dose/volume parameter (IMRT)
V
o
l
u
m
e
 
(
c
c
)Radiation Oncology 2008, 3:4 http://www.ro-journal.com/content/3/1/4
Page 12 of 15
(page number not for citation purposes)
objectives. The incorporation of multicriteria optimiza-
tion in comparative inverse treatment planning studies in
RT may provide more accurate and fare data in ranking of
various RT techniques.
In this study, no attempt was made to escalate the dose
beyond 72.6 GyE for any T stage. The reasons for this deci-
sion were, firstly, that reported local recurrences in IMRT
studies of NPC patients who received radiobiologically
equivalent doses, as in the current study, were attributed
only to more advanced (T3–T4) tumors [6,7,17] which
did not warrant further dose-escalation for T1–T2 tumors.
Secondly, in T3–T4 tumors, Dmax calculated in a single
voxel for the temporal lobes was already in the order of 67
GyE in both IMRT and IMPT plans, reflecting the limita-
tions of both techniques when it comes to reducing max-
imum doses in OARs in the vicinity of the target. Dose-
escalation to partial volumes of the primary tumor (boost
within the boost volume), especially for the hypoxic
regions which can be identified by functional imaging, is
an option to be explored with both techniques. Boost
within the boost principle might alternatively be applied
to residual tumor mass after certain delivered dose.
Locoregional recurrences of NPC without distant failure
are believed to be potentially curable [28]. However, in
salvage therapy of local recurrences, the success of intrac-
avitary brachytherapy or nasopharyngectomy is restricted
to the limited target volumes and application of external
RT with photons is associated with severe side effects [28].
Reduction of the integral doses to several OARs, including
the spinal cord in primary treatment of NPC with IMPT
could leave more room for optimal target treatment and
sparing of critical structures in re-irradiation situations.
Furthermore, despite the promising role of IMRT in local/
locoregional tumor control of NPC, systemic failure still
occurs in many patients, yielding 4-year distant metas-
tases-free rates as low as 66% [6]. Accordingly, combined
chemoradiotherapy is recommended for locoregionally
advanced NPC [29], which necessitates implementation
of new RT techniques whose side effects are less potenti-
ated in a multimodal treatment setting.
Xerostomia is one of the most common RT-related side
effects in NPC patients. Although our IMPT plans could
significantly reduce the averaged Dmean of parotids (36.3
vs. 40.0 GyE), the obtained mean values for both tech-
niques were higher than those reported by other proton
(25.8 – 33 GyE) and IMRT (33–35.2 GyE) studies
[6,7,10,11,17]. Different results in parotid sparing may
relate to variations in target volume definition, especially
for elective neck treatment. In the current study, deep
parotid lobes were always included in PTV-Ns which inev-
itably lead to relatively higher Dmean values in the major-
ity of the glands.
Therapy-induced hearing deterioration is another fre-
quent complaint in NPC patients [30]. It has been sug-
gested that mean doses of 45–48 GyE (32 GyE in children)
to inner ears can lead to significant loss of hearing [31-
33], which supports the benefits of our IMRT and IMPT
plans in lowering the averaged Dmean of inner ears (36.1
GyE vs. 13.1 GyE). However, only IMPT could keep the
Dmean low enough for all patients and ears, a finding,
which is especially beneficial in locoregionally advanced
NPC for which cisplatin-based chemotherapy is often
used. For middle and external ears, the averaged Dmean
was reduced by a factor of 3 by IMPT, which is especially
appreciated considering the report of a 30% incidence rate
of otitis media in 20 NPC patients who had received an
IMRT dose of 72 GyE (2.4 GyE/fraction) [17].
The rate of moderate to severe trismus in NPC patients
treated by traditional RT techniques can be as high as 30%
[4]. In the case of the TM joints, 50 GyE is reported as the
critical level for induction of apparent trismus even
though, functional joint impairments have been reported
with doses as low as 15 GyE [34], supporting the benefits
of IMPT as shown in this study.
The carcinogenic effect of ionizing radiation has been a
matter of debate, especially for low-dose irradiated vol-
umes. In a long-term follow-up of the 28,008 Swedish
infants irradiated for skin hemangioma, Karlsson et al.
[35] found a strong linear dose-response relationship
between absorbed dose in the brain and subsequent risk
of developing an intracranial tumour. In their study, the
mean intracranial doses in the total cohort and in the
individuals developing tumors were estimated as 0.07 GyE
and 0.31 GyE, respectively. In another survey of 53
patients with second malignancies after irradiation to dif-
ferent anatomical locations, most of the tumors were
found in the volume receiving ≤ 6 GyE [36]. In our study,
the averaged volumes of 0.33 GyE to 13.2 GyE were more
than doubled by IMRT, which is of great concern espe-
cially in children. The pediatric patients account for
between 1–18% of all NPC cases [37] and they are often
treated using the same RT guidelines established for
adults. In a survey of 33 cases of childhood NPC treated
with older RT techniques to a median dose of 60 GyE, the
10-year actuarial rate of severe complications was
reported to be as high as 24% and two cases of second
malignancies in salivary glands were observed after
median latency of eight years [38]. Among other side
effects, iatrogenic endocrine insufficiency is often
observed in children who received RT to the head and
neck region due to the inclusion of the hypothalamic-
pituitary axis and thyroid gland in the radiation fields.
Our IMPT plans reduced the averaged Dmean of the thy-
roid gland by a factor of two. However, for the pituitary
gland, neither technique was able to reduce the DmeanRadiation Oncology 2008, 3:4 http://www.ro-journal.com/content/3/1/4
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values sufficiently for locally advanced tumors. In general,
it seems that for pediatric NPC patients, IMPT combined
with the spot-scanning technique is the best RT option for
sparing OARs and minimizing the risk of second malig-
nancies. Since collimation, compensation, and scattering
are not applied in spot-scanning of protons, the risk of
neutron contamination and consequent malignancy
induction is also reduced [39].
It is imperative to acknowledge some pitfalls of using pro-
tons in NPC patients as the dose to the skin surface, espe-
cially in cases with large and bilateral lymph node
metastases. In our study, the averaged Dmax for skin was
equal for IMPT and IMRT techniques (66 GyE) and aver-
aged Dmean was low (< 10 in GyE) in both techniques.
Although treatment planning systems can fall short in
accurate dose calculations in the skin, our results suggest
that acute skin toxicities should not be any more severe in
IMPT than IMRT of NPC patients. Severe skin reactions are
probably more of a problem with passive scattering single
field proton therapies.
For the IMPT plannings, we used a standard proton pencil
beam algorithm with x-ray CT-based path length scaling.
Possible errors in conversion from CT numbers to stop-
ping power of proton pencil beams (range errors) espe-
cially in the presence of complex air-bone interfaces along
the proton beam path in the nasopharyngeal region could
be a source for uncertainties in the Bragg peak position-
ing. Application of a Monte Carlo based treatment plan-
ning algorithm could have modelled the complex
geometries involved in IMPT of NPC patients more accu-
rately and thereby it could have reduced the probability of
range errors [40]. For complex and highly accurate RT
delivery techniques such as IMRT and IMPT, knowledge of
the exact location of the targets and OARs prior to each RT
treatment is also essential. This is especially important in
proton therapy since changes in the tissue heterogeneities
due to shrinkage of the tumor mass, weight loss or devel-
opment of sinusitis as in RT of NPC patients may all cause
range-shifting of the proton beams considerably. These
together with deviations of the target position in daily
setup of the patients may induce significant real time cold
and hot spots within and outside the target. Such prob-
lems can be minimized by application of Image-guided
proton therapy (IGPT) during the course of the treatment.
Based on the acquired information, both correction for
the daily deviations of the target position and modifica-
tions of the treatment plans in case of significant changes
in the patient geometry become possible. IGPT can be
accomplished by using in-room CTs like linac attached x-
ray systems, CT scanner on rails, or functional treatment
verification imaging based on the reconstruction of posi-
tron emission tomography signals derived from the
nuclear interactions in the trajectory of proton beams
[41].
Another issue to consider in IMPT plannings is the uncer-
tain RBE values at the distal edge of spread-out Bragg
Peaks abutting neural structures. While expected varia-
tions of RBE values for locally limited NPC with longer
distance to neural tissues will have no practical impact in
the primary treatment of the lesions, there are grounds for
concern for tumors growing in the vicinity of these struc-
tures. In the current study, more strict dose constraints
were chosen for critical OARs, partially based on the small
uncertainties in the range of the protons and distal-edge
RBE effects in IMPT plans. For instance, we defined Dmax
for both surface and center of the brainstem and optic
apparatus as 60 GyE and 54 GyE, respectively. Although
clinically relevant for both techniques, these dose con-
straints were lower than what is currently used by some
proton therapy centers (<64 GyE as surface dose for brain-
stem and <60 GyE for the optic apparatus) [42]. A more
attractive approach would be to implement methods to
estimating 3D RBE variations within target and non-target
volumes and to consider them during the optimisazion of
the IMPT plans, as presented by Wilkens et al. [43] for
prostate cancer. Although their method was based on
experimental and in vitro data, it seemed to be a promis-
ing step for better clinical evaluation and optimization of
IMPT plans.
In the end, we do acknowledge that until we have power-
ful models to predict the accurate positioning of spread-
out Bragg peaks of the protons and their distal-edge RBE
values before and during course of IMPT, the practical use
of our IMPT planning approach especially with a beam
direction at zero degree may be limited. Furthermore, the
delivery of IMPT in NPC patients with the current
approach demands not only scanning beams but also a
rotating gantry in order to target the tumor with the most
optimal beam directions.
Conclusion
In treatment of NPC, three-field IMPT is dosimetrically
superior to nine-field IMRT concerning tumour coverage
and conformity. However, the major gain with IMPT is the
reduction in the integral doses to several OARs and non-
specific normal tissues. The actual benefits and practical-
ity of this technique for NPC patients can only be verified
through carefully designed clinical trials when IMPT is
available on wider clinical scale.
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